Cardioneuroablation for Reflex Syncope

Syncope, Vasovagal Clinical Trial

— ROMAN  

Official title:

CardioneuROablation for Reflex Syncope: Effects on autonoMic cArdiac Regulation and Efficacy Assessment - the Roman Syncope Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03903744
• Other study ID #: 113/PB/2018
• Status: Completed
• Phase: N/A
• Start date: November 1, 2018
• Est. completion date: February 15, 2022

Study information

• Verified date: April 2022
• Source: Centre of Postgraduate Medical Education
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim. To assess the effects of cardioneuroablation (CNA) on cardiac autonomic regulation and syncope recurrences in patients with vasovagal syncope (VVS), and to compare this novel approach with standard non-pharmacological treatment.

Measurements.

1. Before CNA:

1. Detailed history taking and assessment of eligibility

2. Baseline 12-lead ECG for heart rate assessment, morphology and duration of the P wave and PR interval

3. 24-hour Holter ECG for heart rhythm (mean, minimal, maximal, pauses) and heart rate variability (HRV) assessment

4. Passive tilt test (70 degrees, 45 minutes) to fulfill inclusion criterion and to assess baseline autonomic parameters such as HRV and baroreflex sensitivity (BRS) using sequential method. These parameters will be calculated from 5 min recordings before and after orthostatic stress (tilt).

5. Atropine test - positive response to intravenous atropine in a dose of 2 mg defined as at least 30% increase in sinus rate compared with baseline value

6. Assessment of quality of life using the SF-36 questionnaire

7. Implantable Loop Recorder (ILR) implantation 2-3 days before CNA

2. During CNA:

1. Heart rate before and immediately after CNA

2. Episodes of bradycardia (sinus arrest or atrio-ventricular block) during application of RF to GP.

3. Standard electrophysiological parameters (sinus node recovery time, corrected sinus recovery time, refractory atrio-ventricular node, atrio-ventricular conduction - Wenckebach point, A-H and H-V intervals) will be assessed before an immediately after CNA

4. Atropine test (2 mg) will be repeated immediately after CNA.

3. After CNA:

1. 1-2 days after CNA standard ECG

2. Follow-up: 3, 12 and 24 months after CNA assessment of symptoms, 12 lead standard ECG, control of ILR, 24-hour Holter ECG, tilt test and atropine test will be performed. Additionally, quality of life will be assessed using SF-36 questionnaire

Anticipated results.

1. CNA performed with technique used in the present study is effective in > 90% of patients.

2. CNA-induced changes in analysed ECG and autonomic parameters predict CNA efficacy

Description:

Introduction.

Reflex syncope due to vasovagal reaction is the most frequent cause of transient loss of consciousness (TLOC) in general population. [1-4] It markedly decreases quality of life and may lead to injury. [5, 6] The mechanism of vasovagal syncope (VVS) is complex. One of the most important mechanisms is enhanced parasympathetic activity triggered by abnormal mechanoreceptor reflex and other mechanisms. This leads to prolonged asystole and/or vasodilatation, resulting in syncope. [7] Treatment of VVS remains a challenge. Non-pharmacological treatment such as fluid and salt intake, avoiding situations triggering syncope or tilt training is not effective in a significant proportion of subjects with syncope. Pharmacotherapy is even less effective. Syncope recurs in 25-65% of patients. Alternative therapy, especially in patients with prolonged asystole, is pacemaker implantation, recommended by the guidelines in patients aged > 40 years with documented spontaneous cardioinhibitory VVS and severe symptoms. However, permanent pacing occurs ineffective in at least 25% of patients. In addition, VVS occurs predominantly in young persons in whom permanent pacing should be avoided as much as possible. [8-13] Thus, the need for new treatment options in VVS is clear.

Ablation for atrial fibrillation (AF) has been successfully performed for almost two decades. Apart from pulmonary vein isolation which is a corner stone of AF ablation, autonomic control of the heart is modified by ablation of ganglionated plexi (GP). It has been well documented that in some patients GP ablation increases the success rate of ablation, especially in patients with vagally-mediated AF. Thus, the technique of GP ablation, mainly using the radio-frequency energy, is well established and safe.

Based on data coming from GP ablation during AF procedures, this method has been recently proposed for patients with VVS. The postulated beneficial mechanisms of GP ablation in VVS are attenuation of parasympathetic activity, leading to elimination or reduction reflex asystole and bradycardia. To date, a few case series consisting of up to 70 patients demonstrated very promising results. [15-18]. However, this experience is limited to a few centers. Also, the optimal methodology of the procedure, called cardioneuroablation (CNA) or cardioneuromodulation, is not known. There is no consensus yet as to how many GP's, in both atria or only in the right atrium, in which order and to what extent should be ablated. Moreover, mechanisms responsible for beneficial effects of CNA as well as methods assessing it's efficacy are not clear.

Aim. To assess the effects of CNA on cardiac autonomic regulation and syncope recurrences in patients with VVS, and to compare this novel approach with standard non-pharmacological treatment.

Hypothesis. CNA using GP ablation causes significant changes in autonomic control of the heart, predominantly parasympathetic withdrawal, which is associated with long-term efficacy of the procedure, and is significantly more effective than standard non-pharmacological therapy.

Methods. This is an open-label, randomized, controlled, prospective study.

Study group. Forty consecutive patients with recurrent cardioinhibitory or mixed VVS will be included between August 2018 and July 2021.

The patients will be randomized into 2 groups:

1. Treatment arm (n=20): CNA

2. Control arm (n=20): standard non-pharmacological treatment The patients from the control arm will be allowed to cross over to the CNA group if syncopal episode occurs despite adherence to the non-pharmacological recommendations.

The number of 40 patients will be enough to demonstrate superiority of CNA over standard approach, assuming that the effectiveness of CNA will be over 90%, and the effectiveness of the standard non-pharmacological treatment will be 50%.

Inclusion criteria:

1. At least one documented spontaneous VVS during preceding 12 months or one syncope in history leading to injury and minimum 2 presyncopal events during preceding 12 months, refractory to all recommended types of standard treatment.

2. In case of lack of ECG documentation during spontaneous syncope and history suggesting reflex syncope, at least 3 seconds of asystole due to sinus arrest or atrio-ventricular block with syncope or bradycardia <40 beats per minute with syncope or presyncope during baseline tilt test

3. Sinus rhythm during ECG and tilt test

4. Significantly decreased quality of life due to syncope

5. Positive response to atropine test

6. Obtained written informed consent.

Exclusion criteria:

1. Other possible and treatable causes of syncope such as significant cardiac disease, cardiac arrhythmia or abnormalities of vertebro-basiliar arteries

2. History of stroke or TIA

3. History of cardiac surgery

4. Contraindications to ablation in the right or left atrium

Cardioneuroablation The procedure is performed under mild sedation (midazolam and fentanyl) using a 3.5 mm irrigated tip catheter (Navistar ThermoCool SmartTouch; Biosense Webster, Diamond Bar, California, USA) with contact force module and electroanatomical system Carto 3 (Biosense Webster, Diamond Bar, California, USA). After gaining transseptal access, an electroanatomical map of the right (RA) and left (LA) atrium is created and anatomically-based ablation of GP is performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP by high-frequency stimulation or other imaging techniques.

Measurements.

1. Before CNA:

1. Detailed history taking and assessment of eligibility

2. Baseline 12-lead ECG for heart rate assessment, morphology and duration of the P wave and PR interval

3. 24-hour Holter ECG for heart rhythm (mean, minimal, maximal, pauses) and heart rate variability (HRV) assessment

4. Passive tilt test (70 degrees, 45 minutes) to fulfill inclusion criterion and to assess baseline autonomic parameters such as HRV and baroreflex sensitivity (BRS) using sequential method. These parameters will be calculated from 5 min recordings before and after orthostatic stress (tilt).

5. Atropine test - positive response to intravenous atropine in a dose of 2 mg defined as at least 30% increase in sinus rate compared with baseline value

6. Assessment of quality of life using the SF-36 questionnaire

7. Implantable Loop Recorder (ILR) implantation 2-3 days before CNA

2. During CNA:

1. Heart rate before and immediately after CNA

2. Episodes of bradycardia (sinus arrest or atrio-ventrocular block) during application of RF to GP.

3. Standard electrophysiological parameters (sinus node recovery time, corrected sinus recovery time, refractory atrio-ventricular node, atrio-ventricular conduction - Wenckebach point, A-H and H-V intervals) will be assessed before an immediately after CNA

4. Atropine test (2 mg) will be repeated immediately after CNA.

3. After CNA:

1. 1-2 days after CNA standard ECG

2. Follow-up: 3, 12 and 24 months after CNA assessment of symptoms, 12 lead standard ECG, control ILR, 24-hour Holter ECG, tilt test and atropine test will be performed. Additionally, quality of life will be assessed using SF-36 questionnaire

Definitions used for CNA efficacy assessment:

• Complete efficacy - no syncope or presyncope during two years of follow-up

• Partial efficacy - reduction of the number of syncopal (or presyncopal) episodes or change from syncopal to presyncopal episodes

Primary endpoint

• Time to first syncope recurrence

Secondary endpoints

• Syncope burden (number of syncopal episodes during two years)

• Presyncope burden (number of presyncopal episodes during two years)

• ILR: assessed heart rate and atrio-ventricular conduction if syncope occurs

• CNA-induced changes in autonomic parameters

• Prognostic value of autonomic parameters.

• Safety of CNA: tamponade, stroke, phrenic nerve injury, permanent sinus arrest, local bleeding or vascular complications related to vascular access (hematoma / arteriovenous fistula)

Statistical analysis Results will be presented as mean ± SD or numbers and percentages. Also CNA-induced changes(∆) in analysed parameters will be calculated. The ECG, electrophysiological and autonomic parameters obtained before and after CNA will be compared using student t-test or Mann-Whitney test where appropriate. The values of analysed parameters in predicting CNA efficacy will be assessed by computing sensitivity, specificity, positive and negative predictive value. The ROC curves will be drawn in order to establish optimal cut-off points of analysed parameters in predicting CNA efficacy.

Anticipated results.

1. CNA performed with technique used in the present study is effective in > 90% of patients.

2. CNA-induced changes in analysed ECG and autonomic parameters predict CNA efficacy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 15, 2022
• Est. primary completion date: February 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• At least one documented spontaneous VVS during preceding 12 months or one syncope in history leading to injury and minimum 2 presyncopal events during preceding 12 months, refractory to all recommended types of standard treatment.

• In case of lack of ECG documentation during spontaneous syncope and history suggesting reflex syncope, at least 3 seconds of asystole due to sinus arrest or atrio-ventricular block with syncope or bradycardia <40 beats per minute with syncope or presyncope during baseline tilt test

• Sinus rhythm during ECG and tilt test

• Significantly decreased quality of life due to syncope

• Positive response to atropine test

• Obtained written informed consent.

Exclusion Criteria:

• Other possible and treatable causes of syncope such as significant cardiac disease, cardiac arrhythmia or abnormalities of vertebro-basiliar arteries

• History of stroke or TIA

• History of cardiac surgery

• Contraindications to ablation in the right or left atrium

Related Conditions & MeSH terms

• Syncope
• Syncope, Vasovagal

Intervention

Procedure:
• Cardioneuroablation
The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.

Locations

Country	Name	City	State
Poland	Department of Cardiology, Postgraduate Medical School, Grochowski Hospital	Warsaw	Masovian

Sponsors (1)

Lead Sponsor	Collaborator
Centre of Postgraduate Medical Education

Country where clinical trial is conducted

Poland, 

References & Publications (18)

Aksu T, Golcuk E, Yalin K, Guler TE, Erden I. Simplified Cardioneuroablation in the Treatment of Reflex Syncope, Functional AV Block, and Sinus Node Dysfunction. Pacing Clin Electrophysiol. 2016 Jan;39(1):42-53. doi: 10.1111/pace.12756. Epub 2015 Oct 26. — View Citation

Aydin MA, Mortensen K, Salukhe TV, Wilke I, Ortak M, Drewitz I, Hoffmann B, Müllerleile K, Sultan A, Servatius H, Steven D, von Kodolitsch Y, Meinertz T, Ventura R, Willems S. A standardized education protocol significantly reduces traumatic injuries and — View Citation

Bartoletti A, Fabiani P, Bagnoli L, Cappelletti C, Cappellini M, Nappini G, Gianni R, Lavacchi A, Santoro GM. Physical injuries caused by a transient loss of consciousness: main clinical characteristics of patients and diagnostic contribution of carotid s — View Citation

Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R; International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediat — View Citation

Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martín A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG; ESC Scientific Document Group . 2018 ESC Guidelines for the diagnosis and manageme — View Citation

Chen-Scarabelli C, Scarabelli TM. Neurocardiogenic syncope. BMJ. 2004 Aug 7;329(7461):336-41. Review. — View Citation

Grubb BP. Clinical practice. Neurocardiogenic syncope. N Engl J Med. 2005 Mar 10;352(10):1004-10. Review. — View Citation

Mathias CJ, Deguchi K, Schatz I. Observations on recurrent syncope and presyncope in 641 patients. Lancet. 2001 Feb 3;357(9253):348-53. — View Citation

Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011 Sep;13(9):1231-42. doi: 10.1093/ — View Citation

Piotrowski R, Baran J, Kulakowski P. Cardioneuroablation using an anatomical approach: a new and promising method for the treatment of cardioinhibitory neurocardiogenic syncope. Kardiol Pol. 2018;76(12):1736-1738. doi: 10.5603/KP.a2018.0200. Epub 2018 Oct — View Citation

Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, Brignole M; Vasovagal Syncope and Pacing Trial Investigators. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-indu — View Citation

Romme JJ, van Dijk N, Go-Schön IK, Reitsma JB, Wieling W. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace. 2011 Nov;13(11):1639-47. doi: 10.1093/euro — View Citation

Rose MS, Koshman ML, Spreng S, Sheldon R. The relationship between health-related quality of life and frequency of spells in patients with syncope. J Clin Epidemiol. 2000 Dec;53(12):1209-16. — View Citation

Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA, Moak JP, Sandhu RK, Kanjwal K. 2015 heart rhythm society expert conse — View Citation

Sheldon RS, Morillo CA, Klingenheben T, Krahn AD, Sheldon A, Rose MS. Age-dependent effect of ß-blockers in preventing vasovagal syncope. Circ Arrhythm Electrophysiol. 2012 Oct;5(5):920-6. doi: 10.1161/CIRCEP.112.974386. Epub 2012 Sep 12. — View Citation

Sun W, Zheng L, Qiao Y, Shi R, Hou B, Wu L, Guo J, Zhang S, Yao Y. Catheter Ablation as a Treatment for Vasovagal Syncope: Long-Term Outcome of Endocardial Autonomic Modification of the Left Atrium. J Am Heart Assoc. 2016 Jul 8;5(7). pii: e003471. doi: 10 — View Citation

Tan MP, Newton JL, Chadwick TJ, Gray JC, Nath S, Parry SW. Home orthostatic training in vasovagal syncope modifies autonomic tone: results of a randomized, placebo-controlled pilot study. Europace. 2010 Feb;12(2):240-6. doi: 10.1093/europace/eup368. Epub — View Citation

Yao Y, Shi R, Wong T, Zheng L, Chen W, Yang L, Huang W, Bao J, Zhang S. Endocardial autonomic denervation of the left atrium to treat vasovagal syncope: an early experience in humans. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):279-86. doi: 10.1161/CIRCEP — View Citation

* Note: There are 18 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to first syncope recurrence.	Recurrence of syncope (in days) after using the appropriate method (cardioneuroablation or standard non-pharmacological treatment).	Two-year follow-up after starting treatment.
Secondary	Syncope burden.	Number of syncopal episodes (number of events during two-year follow-up).	Two-year follow-up after starting treatment.
Secondary	Presyncope burden.	Number of presyncopal episodes (number of events during two-year follow-up).	Two-year follow-up.
Secondary	Heart rate and atrio-ventricular conduction if syncope occurs.	Heart rate (beats/min) and longest pause (seconds) (based on ILR monitoring during syncope).	Two-year follow-up.
Secondary	Cardioneuroablation-induced changes in heart rate variability predicting ablation efficacy.	Cardioneuroablation-induced changes in heart rate variability (SDNN in msec) will be analyzed as a predictor of ablation efficacy.	3, 12 and 24 months after cardioneuroablation.
Secondary	Cardioneuroablation-induced changes in baroreflex sensitivity predicting ablation efficacy.	Cardioneuroablation-induced changes in baroreflex sensitivity (msec/mmHg) will be analyzed as a predictor of ablation efficacy.	Two-year follow-up.
Secondary	Complications associated with CNA procedure	Assessment of possible complications: tamponade, stroke, phrenic nerve injury,(permanent sinus arrest, local bleeding or vascular complications related to vascular access (hematoma / arteriovenous fistula) - number of events.	Two-year follow-up.